Nurix (NASDAQ: NRIX) legal chief sells 14,261 shares under 10b5-1 plan

Rhea-AI Filing Summary

Nurix Therapeutics’ Chief Legal Officer, Christine Ring, reported a planned sale of company stock. On 02/09/2026 she sold 14,261 shares of Nurix common stock at a weighted average price of $16.6621 per share under a pre‑arranged Rule 10b5‑1 trading plan. Following this sale, she beneficially owns 42,749 shares of Nurix common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		S(1)		14,261	D	$16.6621(2)	42,749	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.37 and the highest price at which shares were sold was $16.88. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nurix Therapeutics (NRIX) disclose in this Form 4?

Nurix disclosed that Chief Legal Officer Christine Ring sold 14,261 shares of common stock on February 9, 2026. The sale was reported as a code “S” transaction in non-derivative securities, meaning it was an open-market or similar sale of existing common shares.

At what prices did Christine Ring sell Nurix (NRIX) shares in this transaction?

The reported sale used a weighted average price of $16.6621 per share. Footnotes explain that individual trades occurred between a low of $16.37 and a high of $16.88, and full price-by-price details are available upon request from the reporting person.

How many Nurix (NRIX) shares does Christine Ring own after the reported sale?

After the February 9, 2026 transaction, Christine Ring is reported to beneficially own 42,749 shares of Nurix common stock. The filing shows these holdings as direct ownership, following the disposition of 14,261 shares in the open-market sale reported on this Form 4.

Was the Nurix (NRIX) insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states the sale was effected under a Rule 10b5-1 trading plan previously adopted by Christine Ring. Such plans allow insiders to schedule stock trades in advance, providing a structured framework for transactions independent of subsequent possession of material nonpublic information.

Who is the reporting person in this Nurix Therapeutics (NRIX) Form 4 filing?

The reporting person is Christine Ring, who serves as Chief Legal Officer of Nurix Therapeutics, Inc. The Form 4 indicates she is an officer but not a director or 10% owner, and it reports her direct holdings and one sale of common stock on February 9, 2026.